Articles tagged with T Cell Signaling
Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
Researchers discovered a multi-faceted mechanism behind ASD, revealing the gut microbiota and host immune system's influence on disease progression. Precision-selected probiotics restored metabolic balance, reduced neuroinflammation, and ameliorated behavioral abnormalities in ASD mouse models.
Researchers have discovered that glucose aids in T cells' internal communication and boosts their cancer-fighting abilities. T cells allocate significant portions of glucose to build glycosphingolipids, essential for protein production and lipid raft formation, which enhances cell signaling and tumor control.
Researchers have developed a novel synthetic ligand using AI-based computational protein design, activating the Notch signaling pathway in T-cells. This breakthrough enables broadened clinical T-cell production and advances immunotherapy development.
Researchers discovered LAG-3 inhibits T cell activity through spatial proximity to TCR, not ligand binding. This discovery enables precise modulation of autoreactive T cells in autoimmune diseases.
A recent study published in Cell revealed that a specific intestinal immune cell prevents food allergies by breaking the threshold between friend and foe in the gut. Researchers at WashU Medicine identified this cell as RORγt+ dendritic cells, which maintain tolerance to harmless food allergens, preventing allergic reactions.
Researchers identified a method to enhance CAR-T cell therapy by modifying the CUL5 gene. This approach improves T cells' growth and longevity, making them more effective in fighting cancer. The study suggests a new way to create targeted cells using a virus to deliver genetic material.
Researchers at the University of Melbourne have identified a rare type of immune cell, called stem-like T cells, that holds the key to maintaining powerful, long-term immune responses. ID3+ T cells have the remarkable ability to resist burnout and maintain a powerful immune response over time.
Researchers at MD Anderson Cancer Center presented findings on novel treatments for MDS, including luspatercept, which significantly reduced the need for blood transfusions in lower-risk patients. Additionally, a triplet therapy regimen improved survival in older adults with FLT3-mutated AML.
Researchers found that treating the Golgi apparatus with hydrogen sulfide creates T-cells that can take more stress, leading to a better chance of controlling tumors. The study suggests sorting T-cells into high and low Golgi groups could be a new therapeutic target.
Researchers identify interleukin-17A as a key regulator of fat storage, carrying implications for addressing obesity and preventing wasting. The discovery highlights the interaction between the immune system and circadian rhythms, which may hold therapeutic potential for metabolic disorders.
Scientists at St. Jude Children's Research Hospital found that nutrient availability affects T cell development and mitochondrial activity, inhibiting T cell formation in lysosomes. The study highlights the crucial role of organelle signaling, such as mitochondrial and lysosomal function, in shaping tissue immunity.
A new study reveals a connection between NF-κB signaling pathways and X chromosome inactivation in T cells, which has implications for understanding sex-based immune responses. Researchers found that the maintenance of X chromosome inactivation depends on nuclear factor kappa B (NF-κB), a transcription factor.
Researchers at MUSC Hollings Cancer Center discover targeting an immunosuppressive protein on two fronts reduces metastasis and restores sensitivity to immunotherapy in a preclinical model. TNBC cells become resistant to immunotherapy due to membrane instability, enabling PD-L1 protein to drop inside the cell.
Researchers have developed a novel nanoparticle drug-delivery system to activate an immune pathway in combination with tumor-targeting agents, showing promising results in treating pancreatic cancer. Eight out of nine mice tested experienced tumor improvements, including two complete responses.
A new study suggests that an anti-inflammatory antibody treatment can be used to prevent heart transplant rejection. The treatment was found to block an innate immune response that drives dangerous inflammation in transplanted hearts, leading to prolonged organ survival.
Researchers study T cells and monocytes interaction in the meninges before they attack the brain and spinal cord, potentially leading to new disease progression targets. The findings could provide a pathway to treating other neurological diseases like Alzheimer's and Parkinson's.
Researchers identified a fundamental imbalance in immune responses that patients with lupus make, leading to insufficient activation of the aryl hydrocarbon receptor pathway. This imbalance can be corrected by reprogramming disease-causing cells into Th22 cells promoting wound healing, offering a potential cure for lupus.
A team of researchers has discovered a mechanism by which the liver's immune cells are suppressed in chronic hepatitis B, leading to organ damage. The 'sleep timer' function allows immune cells to weaken their activity over time, preventing them from proliferating excessively and causing further damage.
Researchers describe redundant innate immune pathways triggered by AAV vectors, including sensing of viral genome and cytoplasmic DNA sensors. The study highlights the need to understand complex biologic mechanisms underlying adverse reactions to AAV vectors in human gene therapy trials.
Researchers at The Jackson Laboratory discovered a cascade of molecules that help coordinate the attack of cytotoxic T-cells on tumors. Elevated levels of IL-3 reenergize these cells, signaling them to resume detecting and destroying tumors, with rare basophils playing a key role in this process.
Researchers at Weill Cornell Medicine discovered that interleukin-23 acts on group 3 innate lymphoid cells to balance pro-inflammatory effects and maintain gut health. This interaction is impaired in chronic inflammatory bowel diseases, providing new insights into the disease and potential therapeutic targets.
Researchers have identified a subset of intestinal epithelial cells that act as both the major target and responder in a mouse model of gut infection by Citrobacter rodentium. These cells, known as distal colonocytes, trigger a unique gene-expression program when infected with the bacteria.
Researchers at La Jolla Institute for Immunology have developed a new, rapid method to study phosphorylation and other post-translational modifications in immune cells. This method sheds light on signaling pathways that trigger T cell activation and reveals how phosphate groups direct specific gene expression responses.
A team of researchers found that immune cells maintain their alertness through the JAK-STAT signalling pathway when there is no immediate threat. This discovery could lead to new approaches for enhancing the immune system's attention and preventing autoimmune diseases.
A new study developed two machine learning models to quantify CD8+ cell positivity and classify the immunophenotype of cancer specimens in patients with non-small cell lung cancer. The models hold promise for identifying patients who may benefit from immunotherapy.
Researchers from Pusan National University discovered a link between diabetes and periodontitis, showing pro-inflammatory cytokines rise in classical monocytes. The study highlights the systemic impact of these conditions on immune regulation and suggests a potential therapeutic target to reduce diabetes risk.
Researchers discovered that VISTA induces immune suppressor cells called myeloid-derived suppressor cells (MDSCs) through a feedback loop involving STAT3 and polyamines. This pathway has high translational impact for several human cancers, offering promising drug targets.
Researchers at Rice University have discovered a promising new immunological pathway to treat stubborn bone tumors in breast cancer patients. The glyco-immune checkpoint axis, involving protein Siglec-15, plays a crucial role in hiding bone tumors from the immune system.
Researchers have discovered that CD4 and LAG-3 are conserved throughout jawed vertebrate species, including sharks. The study reveals that the cytoplasmic tail motifs of these proteins have opposing immune functions, with CxC/H promoting activation and ITIM-like motif inhibiting cell activity.
Researchers discovered a cell signaling pathway that allows effector memory T cells to drive innate cytokine storms in autoimmune diseases. Targeting the STING pathway may prevent inflammation chain reactions, offering new hope for treating conditions like type 1 diabetes and rheumatoid arthritis.
Scientists have discovered that tissue-resident memory T cells can be enhanced to fight off infections and tumors by redirecting their cholesterol-making process. A drug and statins were found to boost coenzyme Q production in these cells, improving their effectiveness.
Researchers at Gladstone Institutes identified conditions that enable gamma delta T cells to recognize cancer cells by disrupting energy production and causing cellular stress. This insight suggests that therapies manipulating butyrophilin abundance on the surface of cancer cells could boost gamma delta T cell effectiveness.
Researchers identify key protein interactions that control the body's immune response during liver transplantation, leading to improved transplant survival rates. The study found that a specific communication pathway between CEACAM1 and TIM-3 proteins plays a crucial role in controlling the immune response.
Researchers found that IL-6 signaling in allergen-specific T cells was needed to suppress commitment to the harmful Th2 lineage. SOCS3 upregulation by IL-6 inhibits JAK/STAT internal signaling pathway, preventing Th2 cell priming.
Cancer cells have been found to employ a strategy to evade the immune system's killer T cells by interacting with myeloid cells and suppressing type 1 interferon production. This natural pathway is crucial for recruiting killer T cells to combat cancer spread. Researchers hope to develop new therapeutic approaches, such as forcing tumo...
Researchers at H. Lee Moffitt Cancer Center & Research Institute discovered a new way to activate dendritic cells, which can produce strong anti-tumor immunity. The approach uses an oncolytic virus expressing CD40 ligand and IFNβ, reducing tumor size and activating immune cells in patients with non-small cell lung cancer.
Researchers have discovered that inhibiting conventional signalling pathway by disrupting LCK allows more efficient tumour cell killing, using FYN protein instead. This approach enhances T-cell function and reduces graft-versus-host disease, making CAR-T therapy more accessible to patients.
Researchers found that certain gene signaling pathways, such as interferon γ and beta-catenin, can lead to tumor hyperprogression after immunotherapy. Targeting these pathways may prevent hyperprogression in preclinical models.
The study reveals that coronin proteins regulate T cell population size by promoting survival signals when cells are not too crowded. This mechanism is evolutionarily conserved in both humans and slime molds, opening up new avenues for research.
A research study led by Mabel Vidal identified a common genetic signature among infiltrating T cells of different cancer types. The study used AI to analyze data from public repositories and confirmed the results through proteomics experiments.
The study found that protein kinase CK2 plays a key role in regulating CD8+ T cell activation, metabolic reprogramming and differentiation during infection by the intracellular pathogen Listeria monocytogenes. In mouse models, deletion of the CK2α catalytic subunit impaired CD8+ T cell function.
Researchers found that ruxolitinib, a clinically approved drug, suppresses ICB-resistant melanomas by reprogramming TILs and relying on host TNF signaling. This discovery offers a potential target for bypassing therapeutic resistance in advanced melanoma patients.
Researchers at LSU Health New Orleans have identified a critical immunosuppressive pathway and developed an experimental inhibitor to protect T-cells from weakening. The CBL-B inhibitors show great potential in enhancing the efficacy of cancer immunotherapy, making patients' T-cells more effective in killing cancer cells.
The Hackensack Meridian Center for Discovery and Innovation's CDI laboratory has identified critical regulators controlling T-cell homeostasis. The findings could lead to improved cancer therapies and vaccines of the future by modulating the human immune system.
A novel subset of CD8+ regulatory-like T cells (CD8+TRLs) has been identified as 'first responders' to stroke, providing fast-acting and lasting protection. These cells reach the brain within 24 hours after stroke onset, releasing molecules that provide direct neuroprotective effects.
A study published by the University of Alabama at Birmingham found that T cell-derived interleukin-22 plays a crucial role in antibacterial defense of colonic crypts. The researchers discovered that two types of immune cells, innate and adaptive, have distinct roles in defending against pathogenic bacteria.
Researchers at Johns Hopkins Medicine discovered a critical step in the molecular circuitry of immune cells that mobilizes the immune system to fight off foreign invaders. The findings, published in iScience, shed light on subtle genetic variations among human populations that may explain individual responses to infections.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
A new study from the La Jolla Institute for Immunology reveals that two groups of regulatory CD4+ T cells develop at different times to combat acute inflammation. The early Tregs reduce autoimmune damage, while the second wave shuts down the entire immune response to signal infection clearance.
Researchers discovered that cancer cells use a combination of proteins to repel T cells and protect themselves from the immune system. By disabling this protection, scientists were able to allow T cells to infiltrate and attack pancreatic tumors, leading to shrinkage or disappearance.
Scientists at the University of Basel have discovered a new signaling pathway that enables T cells to survive for decades. Coronin 1 regulates this pathway, which suppresses T cell death by maintaining PI3Kdelta activity. This finding has significant implications for understanding and controlling immune function.
Researchers discovered that infections improve the production and function of naïve T cells, the body's first line of defense against disease. This mechanism involves interleukin 7 and MHC molecules, which signal naïve T cells to stay alive and receive optimal metabolic signals.
Researchers comprehensively review T-cell responses to respiratory viral infections and chronic obstructive pulmonary disease (COPD), highlighting key characteristics of peptide-reactive T-cells. The review aims to improve understanding of the underlying mechanisms, leading to more effective immune protection and treatment methods.
Researchers discovered that T cells respond differently to immune signals based on their 'training', revealing a continuum of memory experience. This spectrum affects how fast a cell can respond and what signals it can respond to.
Research suggests that weakened metabolism of immune T cells, specifically one-carbon metabolism, may contribute to age-related immunity loss. Adding small-molecule compounds that boost T cell performance could potentially restore immune function.
Researchers at Fred Hutchinson Cancer Center compared two common CAR designs in lab models and found that the CD28 CAR showed faster and stronger activity, while the 4-1BB CAR was more effective in clearing cancer cells. The study provides insights into how to improve immunotherapy by designing future generations of CAR T-cell therapies.
Researchers found that loss of liver kinase B1 (LKB1) in regulatory T cells disrupts cell metabolism and function, leading to functional exhaustion. This may contribute to allergic reactions and autoimmune disorders like asthma, multiple sclerosis, and lupus.
A new study has identified a critical molecular mechanism that operates in memory T cells, which could be manipulated to produce and maintain more memory T cells. This finding could lead to improved vaccinations and cancer immunotherapies by enhancing the production of memory T cells.